洛美沙星联合阿奇霉素治疗支原体肺炎的疗效观察

Efficacy of Lomefloxacin joint Azithromycin Treatment of Mycoplasma Pneumonia

目的探讨洛美沙星联合阿奇霉素治疗支原体肺炎的疗效及安全性。方法选取2009年至2011年我院收治的支原体肺炎患者90例随机分为两组,对照组和治疗组患者均给予5%阿奇霉素静脉滴注,治疗组在阿奇霉素滴注的同时给予洛美沙星静脉滴注治疗。治疗前后观察患者体温改善情况、咳痰、呼吸困难、肺部啰音等变化;肺部X线纹理改善情况,记录患者治愈时间、治疗中出现的不良反应以及不良反应持续时间等。结果治疗组患者体温恢复时间、咽痛消失时间及胸片病灶消失时间明显小于对照组,二者存在显著差异;两组患者在治疗后CRP与WBC均明显降低,治疗前后指标存在显著差异(P<0.05);治疗组疗效显著高于对照组;两组患者不良反应发生无显著差异。结论洛美沙星联合阿奇霉素治疗支原体肺炎疗效好,且未增加不良反应发生率,值得临床进一步推广。

Objective To investigate the efficacy and safety of treatment ofmycoplasma pneumonia in lomefloxacin plus azithromycin. Methods 2009-2011 90 cases mycoplasma pneumonia patients in our hospital were randomly divided into two groups, the control group and the treatment group patients were given intravenous infusion of 5% azithromycin treatment group given azithromycin infusion while lomefloxacin vein infusion therapy. Observe the patient＇s temperature before and after treatment to improve the situation, changes in sputum, dyspnea, pulmonary rales; lung X-ray texture to improve the situation, records cure time, treatment side effects and duration of adverse reactions in patients. Results In patients treated with hypothermia recovery, sore throat disappeared and the chest X-ray lesions disappear time is significantly less than the control group, there are some notable differences; two groups of patients after treatment, CRP and WBC were significantly lower indicators there are significant differences before and after treatment （P〈0.05）; treatment group was significantly higher than that of the control group; incidence of adverse reactions of the two groups of patients was no significant difference. Conclusion The lomefloxacin joint azithromycin effective treatment of mycoplasma pneumonia, and did not increase the incidence of adverse reactions, and worthy of further promotion.